Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG001 plus nab-paclitaxel in advanced triple-negative breast cancer
CTR20212240Phase 2Active
- Sponsor
- Shangjian Bio
- Start
- Sep 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PBI-1308, paclitaxel in triple-negative breast cancer (TNBC), sponsored by Shangjian Bio. Started Sep 2021; status: active.
02
Drugs
PBI-1308paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20212240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212240.